Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan-Reference-Cited by-同舟云学术

Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan

Published:2021-03-13 Issue:4 Volume:38 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Muto Yumina,Narita Shintaro^ORCID,Hatakeyama Shingo,Maita Shinya,Chiba Shuji,Kubo Kyohei,Aoyama Yuu,Ito Ryuichi,Takahashi Yoshiko,Takahashi Shuhei,Nakamura Kumiko,Honma Naoko,Sato Hiromi,Koizumi Atsushi,Igarashi Ryoma,Okane Katsumi,Ishida Toshiya,Horikawa Yohei,Kumazawa Teruaki,Akihama Susumu,Shimoda Jiro,Suzuki Takehiro,Ohyama Chikara,Habuchi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-021-01480-3.pdf

Reference25 articles.

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937.

2. Tsao CK, Oh WK. First-line treatment of hormone-sensitive metastatic prostate cancer: is there a single standard of care? J Clin Oncol. 2018. https://doi.org/10.1200/jco.2017.77.4315.

3. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. https://doi.org/10.1056/NEJMoa1503747.

4. Barata PC, Sartor AO. Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or. Cancer. 2019;125(11):1777–88. https://doi.org/10.1002/cncr.32039.

5. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60. https://doi.org/10.1056/NEJMoa1704174.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health‐related quality of life the first year after a prostate cancer diagnosis a systematic review;International Journal of Urological Nursing;2023-01-05

2. Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective study;The Prostate;2022-06-23

3. Management of prostate cancer in older patients;JPN J CLIN ONCOL;2022

4. Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration‐sensitive prostate cancer: A multicenter retrospective study;International Journal of Urology;2022-03-16

5. Management of prostate cancer in older patients;Japanese Journal of Clinical Oncology;2022-02-25